<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03797196</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMIZE</org_study_id>
    <nct_id>NCT03797196</nct_id>
  </id_info>
  <brief_title>RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients</brief_title>
  <acronym>OPTIMIZE</acronym>
  <official_title>Open Label Multicenter Randomized Trial Comparing Standard Immunosuppression With Tacrolimus and Mycophenolate Mofetil With a Low Exposure Tacrolimus Regimen in Combination With Everolimus in de Novo Renal Transplantation in Elderly Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, randomized, multicenter, intervention trial comparing standard immunosuppression
      with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen in
      combination with everolimus.

      The primary objective is to test the hypothesis that an age-adapted immunosuppressive regimen
      targeted at reduced immunosuppression with low calcineurin inhibitor (tacrolimus) exposure in
      combination with everolimus will result in improved outcome in elderly recipients of A:
      Kidneys from older deceased donors (&gt;64 years) and B: Kidneys from living donors (all ages)
      and younger deceased donors (&lt;65 years).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study two immunosuppressive regimes will be tested; In both groups basiliximab
      induction will be applied. Additionally, the standard therapy consisting of prednisolone,
      mycophenolic acid and tacrolimus once-daily (Envarsus®), or the comparator in which
      mycophenolic acid will be replaced by everolimus combined with strongly reduced levels of
      tacrolimus once-daily (Envarsus®). When not tolerated,tacrolimus may be replaced by
      ciclosporin. The hypothesis is that reduced calcineurin inhibitor (CNI) exposure in
      combination with everolimus will lead to improved allograft function, a reduced incidence of
      complications and improved quality of life.

      This study will consist of two strata: Stratum A: Elderly recipients (≥65 years) of kidneys
      from elderly deceased donors (≥65 years) within the Eurotransplant Senior Program. Stratum B:
      Elderly recipients (≥65 years) of kidneys from living donors (all ages) or deceased donors
      (&lt;65 years). The primary endpoint will be &quot;successful transplantation&quot; which is defined as
      survival with a functioning allograft with a minimum estimated GFR of 30 ml/min per 1.73 m2
      in stratum A and 45 ml/min per 1.73 m2 in stratum B, after 2 years.

      The study will be performed by the Dutch transplant centers and the Dutch Kidney Patient
      Organization (NVN) will participate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>successfull transplantation</measure>
    <time_frame>24 months</time_frame>
    <description>The overall primary study endpoint &quot;successful transplantation&quot; as defined for the individual strata and analyzed for the whole study population.
Stratum A: Primary endpoint: successful transplantation at two years after transplantation defined as: absence of graft or patient loss in the presence of an eGFR above 30 ml/min/1.73m2.
Stratum B: Primary endpoint: successful transplantation at two years after transplantation defined as absence of graft or patient loss in the presence of an eGFR above 45 ml/min/1.73m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>24 months</time_frame>
    <description>patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft loss</measure>
    <time_frame>24 months</time_frame>
    <description>graft survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute rejection</measure>
    <time_frame>24 months</time_frame>
    <description>treated biopsy-proven rejection (tBPAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>estimated Glomerular Filtration Rate below 30 and 45 ml/min/1.73m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of rejection treatment</measure>
    <time_frame>24 months</time_frame>
    <description>type of rejection treatment will be scored by questionnaire to the treating nephrologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evolution of renal function (eGFR) and creatinine clearance over time by slope analysis</measure>
    <time_frame>24 months</time_frame>
    <description>The evolution of renal function (eGFR) and creatinine clearance over time by slope analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events, serious adverse events and adverse reactions</measure>
    <time_frame>24 months</time_frame>
    <description>The incidence of adverse events, serious adverse events and adverse reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of clinically relevant infections, post transplantation diabetes mellitus, malignancies and cardiovascular events</measure>
    <time_frame>24 months</time_frame>
    <description>The incidence of clinically relevant infections, post transplantation diabetes, malignancies and cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of frailty at 3, 12 and 24 months after transplantation and change in frailty from baseline</measure>
    <time_frame>24 months</time_frame>
    <description>frailty is measured by fried frailty index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of T-cell immunosenescence at 12 and 24 months and changes from baseline</measure>
    <time_frame>24 months</time_frame>
    <description>T cell differentiation, exhaustion and telomere length will be assessed by flowcytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL at 0, 12 and 24 months and changes from baseline</measure>
    <time_frame>24 months</time_frame>
    <description>HRQoL is measured by EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of donor-specific anti-HLA antibodies (DSA)</measure>
    <time_frame>24 months</time_frame>
    <description>DSA as measured by Luminex</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">374</enrollment>
  <condition>Renal Transplant Recipients</condition>
  <condition>Elderly Patients</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard tacrolimus with mycophenolate mofetil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose tacrolimus with everolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose tacrolimus in combination with everolimus</intervention_name>
    <description>a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients</description>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard dose tacrolimus with mycophenolate mofetil</intervention_name>
    <description>A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent must be obtained before any assessment is performed

          2. Male or female subject ≥65 years old

          3. Subject randomized within 24 hours of completion of transplant surgery

          4. Stratum A: Recipient of a primary (or secondary, if first graft is not lost due to
             immunological reasons) renal transplant from a deceased donor aged 65 years or older

          5. Stratum B: Recipient of a primary (or secondary, if first graft is not lost due to
             immunological reasons) renal transplant from a deceased donor aged below 65 years or a
             living donor of any age

        Exclusion Criteria:

          -  Exclusion criteria for both stratum A and B

               1. Subject is a multi-organ transplant recipient

               2. Recipient of bloodgroup ABO incompatible allograft or CDC cross-match positive
                  transplant

               3. Subject at high immunological risk for rejection as determined by local practice
                  for assessment of anti-donor reactivity

               4. Recipient of a kidney with a cold ischaemia time (CIT) &gt;24 hr

               5. Recipients of a kidney from an HLA-identical related living donor

               6. Known intolerability for one or more of the study drugs

               7. Subject who is HIV positive

               8. HBsAg and/or a HCV positive subject with evidence of elevated liver function
                  tests (ALT/AST levels ≥2.5 times ULN). Viral serology results obtained within 6
                  months prior to randomization are acceptable

               9. Recipient of a kidney from a donor who tests positive for human immunodeficiency
                  virus

                  (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV)

              10. Subject with a BMI greater than 35 kg/m2

              11. Subject with severe systemic infections, current or within the two weeks prior to

                  randomization

              12. Subject requiring systemic anticoagulation that cannot be temporarily interrupted
                  and which would preclude renal biopsy

              13. History of malignancy of any organ system (other than localized basal or squamous
                  cell carcinoma of the skin), treated or untreated, within the past 5 years,
                  regardless of whether there is evidence of local recurrence or metastases

              14. Subject with severe restrictive or obstructive pulmonary disorders

              15. Subject with severe hypercholesterolemia or hypertriglyceridemia that cannot be
                  controlled

              16. Subject with white blood cell (WBC) count ≤ 2,000/mm3 or with platelet count ≤
                  50,000/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Hesselink, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederike Bemelman, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Malignancy Consortium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Berger, Md, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan-Stephan Sanders, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azam Nurmohamed, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aiko De Vries, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luuk Hilbrands, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arjan Van Zuilen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teun Van Gelder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk Kuypers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leuven MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Berger, MD, PhD</last_name>
    <phone>+31-50-3616161</phone>
    <email>s.p.berger@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan-Stephan Sanders, MD, PhD</last_name>
    <phone>+31-50-3616161</phone>
    <email>j.sanders@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leuven University Hospital</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Kuypers, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederike Bemelman, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Azam Nurmohamed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Berger, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jan-Stephan Sanders, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aiko De Vries, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luuk Hilbrands, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dennis Hesselink, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arjan Van Zuilen, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>J.S.F. Sanders</investigator_full_name>
    <investigator_title>principal investigator, head of renal transplant program UMCG</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

